Clinical trials - Press Releases

Date	Title	Company
09-Jan-2024	Creative Diagnostics Launches New P53 and Tp53 Antibodies for Cancer Research	Creative Diagnostics
09-Jan-2024	Creative Diagnostics Announces MDT Services for Measuring Antibacterial Effectiveness	Creative Diagnostics
09-Jan-2024	Creative Diagnostics Launches Rapid Robenidine Test Reagents for the Analysis of Anticoccidial Residues	Creative Diagnostics
05-Jan-2024	selectION, Inc. to Present Update on Clinical Progress at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 11, 2024	selectION, Inc.
14-Dec-2023	Mission Therapeutics announces US FDA approval to initiate Phase II clinical trial of its lead asset MTX652 in Acute Kidney Injury	Mission Therapeutics
14-Dec-2023	Levicept Completes Recruitment in Phase II Clinical Trial of Neurotrophin Modulator, LEVI-04	Levicept
14-Dec-2023	CellProthera advances towards its Phase III clinical trials with the development of a new potency assay	CellProthera
14-Dec-2023	SiSaf Announces Completion of Patient Enrolment in Phase II Trial of Bio-Courier® Drug Formulation for the Treatment of Mild/Moderate Alopecia Areata	SiSaf
14-Dec-2023	HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China	HUTCHMED
14-Dec-2023	ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)	ADC Therapeutics
14-Dec-2023	1ST Biotherapeutics, Inc. Announces First Patient Dosed in Phase I/II Study of HPK1 Inhibitor FB849 in Patients with Advanced Solid Tumors	1ST Biotherapeutics
14-Dec-2023	Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research	Centricity Research
13-Dec-2023	SiSaf Announces Completion of Patient Enrolment in Phase II Trial of Bio-Courier® Drug Formulation for the Treatment of Mild/Moderate Alopecia Areata	SiSaf
11-Dec-2023	New Data Presented at ASH from the Phase 3 GLOW Study Show Fixed-Duration, First-Line Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrated an Overall Survival Rate of More Than 84 Percent at 54 Months in Patients with Chronic Lymphocytic Leukaemia	Jassen
11-Dec-2023	ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH	ImmunoGen
08-Dec-2023	PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023	PureTech
08-Dec-2023	Vesper Bio doses first volunteer in Phase I study of first-in-class oral treatment for Frontotemporal Dementia (FTD)	Vesper Bio
08-Dec-2023	2cureX Receives Ethical Approval for Groundbreaking HIPEC Clinical Trial	2cureX
05-Dec-2023	Thermosome Appoints Dr. Frank Hermann, MD, as Chief Medical Officer and Adds Prof. Alessandro Gronchi, MD, to Clinical Advisory Board	Thermosome GmbH
30-Nov-2023	PHARMANOVIA STRENGTHENS MEDICAL AFFAIRS TEAM WITH KEY APPOINTMENTS TO SUPPORT GLOBAL GROWTH	Pharmanovia